Your shopping cart is currently empty

Galicaftor (ABBV-2222; GLPG-2222) is a potent and orally active cystic fibrosis transmembrane conductance regulator (CFTR) corrector that enhances CFTR protein folding and trafficking, Galicaftor is widely used in cystic fibrosis research to study CFTR rescue mechanisms, epithelial ion transport, and therapeutic correction of underlying molecular defects.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $88 | - | In Stock | |
| 5 mg | $213 | - | In Stock | |
| 10 mg | $347 | - | In Stock | |
| 25 mg | $695 | - | In Stock | |
| 50 mg | $1,090 | - | In Stock | |
| 100 mg | $1,820 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $263 | - | In Stock |
| Description | Galicaftor (ABBV-2222; GLPG-2222) is a potent and orally active cystic fibrosis transmembrane conductance regulator (CFTR) corrector that enhances CFTR protein folding and trafficking, Galicaftor is widely used in cystic fibrosis research to study CFTR rescue mechanisms, epithelial ion transport, and therapeutic correction of underlying molecular defects. |
| Targets&IC50 | Cl- channel:< 10 nM (EC50) |
| In vitro | In cellular assays using primary patient cells homozygous for the F508del/F508del mutation, Galicaftor demonstrates functional restoration of chloride channel activity with an EC₅₀ of < 10 nM [2]. |
| In vivo | In pharmacokinetic studies conducted in rats, Galicaftor has been evaluated for its physiological properties. Following intravenous (i.v.) administration at a dose of 1 mg/kg, the observed half-life (T1/2) is approximately 2.7 h. When administered via the intragastric (oral) route at 1 mg/kg, the molecule exhibits absorption with an oral bioavailability (%F) of 74%. These parameters support the investigation of the molecule in oral dosing regimens within preclinical animal models [1]. |
| Synonyms | GLPG-2222, GLPG2222, ABBV-2222, ABBV2222 |
| Molecular Weight | 559.46 |
| Formula | C28H21F4NO7 |
| Cas No. | 1918143-53-9 |
| Smiles | C(N[C@H]1C=2C(O[C@H](C1)C3=CC=C(C(O)=O)C=C3)=CC(OC(F)F)=CC2)(=O)C4(CC4)C=5C=C6C(=CC5)OC(F)(F)O6 |
| Relative Density. | 1.56 g/cm3 (Predicted) |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 80 mg/mL (143 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.